Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide

Secondary hormone therapy, abiraterone and enzalutamide, has improved outcomes for metastatic castration-resistant prostate cancer (mCRPC) and prolonged patients’ lives significantly. Various studies have compared the cancer-related outcomes, adverse effects, and drug-induced comorbidities in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yi-Ting, Huang, Yen-Chun, Liu, Chih-Kuan, Lee, Tian-Shyug, Chen, Mingchih, Chien, Yu-Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167063/
https://www.ncbi.nlm.nih.gov/pubmed/34084142
http://dx.doi.org/10.3389/fphar.2021.669236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167063/
https://www.ncbi.nlm.nih.gov/pubmed/34084142
http://dx.doi.org/10.3389/fphar.2021.669236

Ejemplares similares